Header Logo

Connection

RADEK SKODA to Neoplasms

Back to Details
This is a "connection" page, showing publications RADEK SKODA has written about Neoplasms.
RADEK SKODA
Connection Strength
0.431
Neoplasms
  1. Inhibition of interleukin-1? reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022 09 13; 13(1):5346.
    View in: PubMed
    Score: 0.274
  2. Genomic profiling for clinical decision making in?myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.069
  3. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 12 28; 130(26):2848-2859.
    View in: PubMed
    Score: 0.049
  4. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.